Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections
Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant (AMR) infections …
providing up-to-date guidance on the treatment of antimicrobial-resistant (AMR) infections …
Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase–producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii …
Abstract The Infectious Diseases Society of America (IDSA) is committed to providing up-to-
date guidance on the treatment of antimicrobial-resistant infections. A previous guidance …
date guidance on the treatment of antimicrobial-resistant infections. A previous guidance …
Rescuing the last-line polymyxins: achievements and challenges
Antibiotic resistance is a major global health challenge and, worryingly, several key Gram
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical …
BT Tsuji, JM Pogue, AP Zavascki… - … : The Journal of …, 2019 - Wiley Online Library
The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections
RK Shields, DL Paterson… - Clinical Infectious …, 2023 - academic.oup.com
Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) is one of
the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant …
the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant …
Carbapenem-resistant Acinetobacter baumannii: Colonization, Infection and Current Treatment Options
C Bartal, KVI Rolston, L Nesher - Infectious diseases and therapy, 2022 - Springer
Carbapenem-resistant Acinetobacter baumannii (CRAB) causes colonization and infection
predominantly in hospitalized patients. Distinction between the two is a challenge. When …
predominantly in hospitalized patients. Distinction between the two is a challenge. When …
New perspectives on antimicrobial agents: cefiderocol
Bacterial resistance to carbapenem agents has reached alarming levels. Accordingly,
collaborative efforts between national and international organizations and the …
collaborative efforts between national and international organizations and the …
Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options
S Karakonstantis, EI Kritsotakis… - Journal of Antimicrobial …, 2020 - academic.oup.com
Background The literature on the epidemiology, mortality and treatment of pandrug-resistant
(PDR) Gram-negative bacteria (GNB) is scarce, scattered and controversial. Objectives To …
(PDR) Gram-negative bacteria (GNB) is scarce, scattered and controversial. Objectives To …
[HTML][HTML] Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment
Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAB) has gained
global notoriety as a critically important nosocomial pathogen. It mostly affects debilitated …
global notoriety as a critically important nosocomial pathogen. It mostly affects debilitated …
Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach …
The management of carbapenem-resistant infections is often based on polymyxins,
tigecycline, aminoglycosides and their combinations. However, in a recent systematic …
tigecycline, aminoglycosides and their combinations. However, in a recent systematic …